Develop new treatments

CANTAB Connect

Develop new treatments

Characterising cognitive signals in drug development increases the chances of success and reduces the risk of failure in trials.

Our CANTAB Connect assessment products are accepted by regulatory bodies as clinical endpoints. As a primary endpoint, our products can be used to definitively demonstrate the cognitive safety or efficacy of a compound. As secondary or exploratory endpoints, we provide cost-effective and non-invasive means of assaying brain function and patient outcomes, aiding decision-making, dose-finding and drug re-purposing.

Cognitive Safety eCOAs

The industry standard for cognitive safety outcomes measurement

Find out more

Cognitive Efficacy eCOAs

Demonstrate the cognitive efficacy and functional impact of compounds

Find out more

Abuse Liability eCOAs

Regulatory accepted measures of drug abuse potential in clinical studies

Find out more